Is hydroxychloroquine appropriate for treating interstitial lung disease, and what are the recommended dosing and monitoring guidelines?

Hydroxychloroquine is NOT Recommended for Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases

Hydroxychloroquine is explicitly not included in the 2023 ACR/CHEST guidelines for treating ILD associated with systemic autoimmune rheumatic diseases (SARD-ILD), and the most recent high-quality randomized controlled trial showed no benefit for childhood ILD. 1, 2

Evidence Against HCQ for ILD

Guideline Recommendations

The 2023 ACR/CHEST guidelines provide comprehensive treatment algorithms for SARD-ILD across multiple conditions (systemic sclerosis, rheumatoid arthritis, Sjögren's disease, inflammatory myopathies, and mixed connective tissue disease). Hydroxychloroquine is conspicuously absent from all first-line and second-line treatment recommendations 1.

Preferred first-line agents include:

• Mycophenolate (preferred across all SARD-ILD subtypes)
• Rituximab
• Azathioprine
• Tocilizumab (for specific conditions)
• Cyclophosphamide (for progressive disease)

The guidelines specifically recommend against methotrexate, leflunomide, TNF inhibitors, and abatacept for SARD-ILD treatment, noting that "some panelists would stop these medications if ILD developed while using them" 1. While HCQ is not explicitly mentioned in this "avoid" list, its complete absence from treatment algorithms is telling.

Clinical Trial Evidence

The only randomized controlled trial of HCQ in ILD was conducted in childhood ILD 2. This 2022 phase 2, double-blind, placebo-controlled trial found:

• No difference in the primary endpoint (oxygenation changes)
• No difference in secondary endpoints including oxygen saturation, quality of life, pulmonary function, or 6-minute walk distance
• Small effect sizes overall
• The authors concluded that "the small effect size of HCQ treatment observed requires careful reassessments of prescriptions in everyday practice"

Limited Context Where HCQ May Be Considered

ABCA3 Deficiency (Genetic ILD)

HCQ has shown potential benefit in the highly specific context of ABCA3 gene mutations causing childhood ILD 3, 4, 5. However:

• This is a rare genetic disorder, not typical SARD-ILD
• Response appears variant-specific - only certain ABCA3 mutations respond to HCQ 5
• Evidence consists of case reports and small series, not controlled trials
• The mechanism (anti-inflammatory effects or altered intracellular metabolism) differs from typical ILD pathophysiology

Dosing and Monitoring (If Used Off-Label)

If HCQ is prescribed off-label despite lack of evidence, FDA labeling provides critical safety parameters 6:

Dosing:

• Maximum 5 mg/kg actual body weight per day (doses ≥5 mg/kg increase retinal toxicity risk)
• Typical adult dose: 200-400 mg daily

Mandatory Monitoring:

• Baseline ophthalmologic exam within first year including:
  • Best corrected visual acuity
  • Automated visual field testing (central 10 degrees; central 24 degrees for Asian patients)
  • Spectral domain optical coherence tomography
• Annual eye exams for high-risk patients (renal impairment, concurrent tamoxifen, macular disease)
• Annual eye exams after 5 years for standard-risk patients
• Periodic blood counts (risk of myelosuppression)
• Liver function tests if symptoms suggest hepatotoxicity
• Cardiac monitoring (QT prolongation risk)

Critical Warnings:

• Irreversible retinal damage related to cumulative dose and duration
• Risk factors: duration >5 years, renal impairment, concurrent tamoxifen
• Serious skin reactions (SJS, TEN, DRESS)
• Neuropsychiatric reactions including suicidality
• Severe hypoglycemia
• Skeletal muscle myopathy

Clinical Bottom Line

For SARD-ILD, use mycophenolate as first-line therapy 1. If HCQ is already prescribed when ILD develops, consider discontinuation and transition to evidence-based agents. The 2023 guidelines represent expert consensus from both rheumatology and pulmonology societies, based on systematic evidence review using GRADE methodology.

For genetic ILD (ABCA3 deficiency), HCQ may be considered in consultation with specialized centers, recognizing this is based on case series rather than controlled trials 3, 4, 5.

The absence of HCQ from modern ILD treatment algorithms, combined with negative RCT data and significant toxicity risks requiring intensive monitoring, makes it an inappropriate choice for SARD-ILD when superior alternatives exist.